Atria's edge is structural, and the core conviction of the fund is that the buyers of compute, AI and drug discovery platforms are concentrated in a few hundred decision-makers across the top 20 largest global biopharma companies. Chris Leiter spent a decade inside, selling into and partnering with that network, from negotiating multi-billion-dollar licensing transactions, to investing on the venture side on behalf of industrial heavyweights like Novartis, to founding a company that sold technology to clinical teams. That access lets Atria's portfolio companies reach C-suite pharma buyers and business development & partnering leaders, leading to an unfair distribution and partnering advantage early on in company building.